205 related articles for article (PubMed ID: 24966587)
41. Nucleos(t)ide analog(s) prophylaxis after hepatitis B immunoglobulin withdrawal against hepatitis B and D recurrence after liver transplantation.
Cholongitas E; Goulis I; Antoniadis N; Fouzas I; Imvrios G; Giakoustidis D; Giouleme O; Papanikolaou V; Akriviadis E; Vasiliadis T
Transpl Infect Dis; 2016 Oct; 18(5):667-673. PubMed ID: 27421122
[TBL] [Abstract][Full Text] [Related]
42. De novo entecavir+adefovir dipivoxil+lamivudine triple-resistance mutations resulting from sequential therapy with adefovir dipivoxil, and lamivudine.
Yang S; Xing H; Wang Q; Wang X; Liu S; Cheng J
Ann Clin Microbiol Antimicrob; 2016 Apr; 15():24. PubMed ID: 27079793
[TBL] [Abstract][Full Text] [Related]
43. [HBV vaccine escape mutations in a chronic hepatitis B patient treated with nucleos(t)ide analogues].
Sayan M; Buğdacı MS
Mikrobiyol Bul; 2013 Jul; 47(3):544-9. PubMed ID: 23971933
[TBL] [Abstract][Full Text] [Related]
44. Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B.
Dakin H; Fidler C; Harper C
Value Health; 2010 Dec; 13(8):934-45. PubMed ID: 20825624
[TBL] [Abstract][Full Text] [Related]
45. Efficacy and safety of long-term therapy with nucleos(t)ide analogues in chronic hepatitis B.
Ibragimov EK; Abdurakhmanov DT; Rozina TP; Nikulkina EN; Tanaschuk EL; Odintsov AV; Panevkina SV; Moiseev SV
Ter Arkh; 2019 Mar; 91(2):40-47. PubMed ID: 31094170
[TBL] [Abstract][Full Text] [Related]
46. Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B infection.
Jones J; Colquitt J; Shepherd J; Harris P; Cooper K
Health Technol Assess; 2010 May; 14 Suppl 1():23-9. PubMed ID: 20507800
[TBL] [Abstract][Full Text] [Related]
47. Tenofovir rescue therapy in pregnant females with chronic hepatitis B.
Hu YH; Liu M; Yi W; Cao YJ; Cai HD
World J Gastroenterol; 2015 Feb; 21(8):2504-9. PubMed ID: 25741161
[TBL] [Abstract][Full Text] [Related]
48. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses.
Woo G; Tomlinson G; Nishikawa Y; Kowgier M; Sherman M; Wong DK; Pham B; Ungar WJ; Einarson TR; Heathcote EJ; Krahn M
Gastroenterology; 2010 Oct; 139(4):1218-29. PubMed ID: 20600036
[TBL] [Abstract][Full Text] [Related]
49. Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance.
Sarrecchia C; Svicher V; Volpi A; Salpini R; Ceccarelli L; Sordillo P; Bertoli A; Perno CF; Andreoni M
Infection; 2011 Aug; 39(4):367-70. PubMed ID: 21674358
[TBL] [Abstract][Full Text] [Related]
50. [Nucleoside and nucleotide analogs in the treatment of chronic hepatitis B].
Buti M
Enferm Infecc Microbiol Clin; 2008 May; 26 Suppl 7():32-8. PubMed ID: 19100229
[TBL] [Abstract][Full Text] [Related]
51. Prevention of lamivudine-resistant hepatitis B recurrence after liver transplantation with entecavir plus tenofovir combination therapy and perioperative hepatitis B immunoglobulin only.
Karlas T; Hartmann J; Weimann A; Maier M; Bartels M; Jonas S; Mössner J; Berg T; Tillmann HL; Wiegand J
Transpl Infect Dis; 2011 Jun; 13(3):299-302. PubMed ID: 21159112
[TBL] [Abstract][Full Text] [Related]
52. Multiple drug-resistant HBV mutation may contribute to poor response of adefovir + entecavir in entecavir-resistant patients.
Shao J; Liu Y; Liu LM; Chen R; Zhao L; Zhou Y; Li L; Li X; Li J; Xu D
J Infect Dev Ctries; 2021 Jan; 15(1):131-140. PubMed ID: 33571155
[TBL] [Abstract][Full Text] [Related]
53. Comparison of re-treatment outcomes of lamivudine plus adefovir or entecavir in chronic hepatitis B patients with viral relapse after cessation of adefovir.
Wang JC; He LL; Chen Q
Eur Rev Med Pharmacol Sci; 2013 May; 17(9):1162-6. PubMed ID: 23690184
[TBL] [Abstract][Full Text] [Related]
54. Treatment of HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues.
Papatheodoridis GV
Liver Int; 2011 Jan; 31 Suppl 1():95-103. PubMed ID: 21205145
[TBL] [Abstract][Full Text] [Related]
55. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
Iannazzo S; Coco B; Brunetto MR; Rossetti F; Caputo A; Latour A; Espinos B; Bonino F
Antivir Ther; 2013; 18(4):623-33. PubMed ID: 23486701
[TBL] [Abstract][Full Text] [Related]
56. Chronic hepatitis B genotype E in African migrants: response to nucleos(t)ide treatment in real clinical practice.
Cuenca-Gómez JÁ; Lozano-Serrano AB; Cabezas-Fernández MT; Soriano-Pérez MJ; Vázquez-Villegas J; Estévez-Escobar M; Cabeza-Barrera I; Salas-Coronas J
BMC Infect Dis; 2018 Nov; 18(1):568. PubMed ID: 30428845
[TBL] [Abstract][Full Text] [Related]
57. Optimal therapy of chronic hepatitis B: how do I treat my HBeAg-negative patients?
Viganò M; Invernizzi F; Lampertico P
Liver Int; 2015 Jan; 35 Suppl 1():107-13. PubMed ID: 25529095
[TBL] [Abstract][Full Text] [Related]
58. HBeAg-positive chronic hepatitis B: why do i treat my patients with Nucleos(t)ide analogs?
Buti M
Liver Int; 2014 Feb; 34 Suppl 1():108-11. PubMed ID: 24373086
[TBL] [Abstract][Full Text] [Related]
59. Unsuccessful therapy with adefovir and entecavir-tenofovir in a patient with chronic hepatitis B infection with previous resistance to lamivudine: a fourteen-year evolution of hepatitis B virus mutations.
Cassino L; Benetti S; Fay F; Tanno H; Quarleri J
BMC Infect Dis; 2011 Jun; 11():178. PubMed ID: 21696601
[TBL] [Abstract][Full Text] [Related]
60. Cost effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B from a Canadian public payer perspective.
Dakin H; Sherman M; Fung S; Fidler C; Bentley A
Pharmacoeconomics; 2011 Dec; 29(12):1075-91. PubMed ID: 22077579
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
